{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:27:41Z","timestamp":1792103261829,"version":"4.4.0"},"reference-count":39,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,12,30]],"date-time":"2014-12-30T00:00:00Z","timestamp":1419897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2015,5]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Photochemical treatment (<jats:styled-content style=\"fixed-case\">PCT<\/jats:styled-content>) of platelet concentrates using photosensitizers and ultraviolet light illumination reduces the proliferation potential of pathogens by damaging biomolecules.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>The impact of riboflavin (<jats:styled-content style=\"fixed-case\">RF<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PRT<\/jats:styled-content>)\u2010 and amotosalen (<jats:styled-content style=\"fixed-case\">AS<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PCT<\/jats:styled-content>)\u2010based pathogen inactivation on platelets was studied using microfluidic flow chambers on immobilized collagen using standard platelet concentrates prepared from buffy coats in additive solution. Flow cytometry, metabolic parameters and light transmission aggregometry with thrombin\u2010related peptide, collagen and ristocetin were determined concurrently.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Both<jats:styled-content style=\"fixed-case\">PCT<\/jats:styled-content>s significantly decreased the platelet surface coverage kinetics in flow chambers over the course of the 7\u2010day study. Platelet aggregation was affected following<jats:styled-content style=\"fixed-case\">RF<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PRT<\/jats:styled-content>in response to all agonists, while<jats:styled-content style=\"fixed-case\">AS<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PCT<\/jats:styled-content>mainly impacted low\u2010dose ristocetin agglutination.<jats:styled-content style=\"fixed-case\">RF<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PRT<\/jats:styled-content>induces premature platelet activation because integrin \u03b1<jats:styled-content style=\"fixed-case\"><jats:sub>II<\/jats:sub><\/jats:styled-content><jats:sub>b<\/jats:sub>\u03b2<jats:sub>3<\/jats:sub>was spontaneously activated, and \u03b1\u2010degranulation, phosphatidylserine\/\u2010ethanolamine exposure and anaerobic metabolism significantly increased following treatment, which was not the case for<jats:styled-content style=\"fixed-case\">AS<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PCT<\/jats:styled-content>. On the other hand,<jats:styled-content style=\"fixed-case\">AS<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PCT<\/jats:styled-content>significantly diminished thrombus growth onto von Willebrand factor under shear flow. This defect was caused by fewer integrin \u03b1<jats:styled-content style=\"fixed-case\"><jats:sub>II<\/jats:sub><\/jats:styled-content><jats:sub>b<\/jats:sub>\u03b2<jats:sub>3<\/jats:sub>interactions, not by defective<jats:styled-content style=\"fixed-case\">GPI<\/jats:styled-content>b\u03b1\u2010<jats:styled-content style=\"fixed-case\">VWF<\/jats:styled-content>binding as shown by adhesion experiments in the presence of tirofiban. Moreover, integrin \u03b1<jats:styled-content style=\"fixed-case\"><jats:sub>II<\/jats:sub><\/jats:styled-content><jats:sub>b<\/jats:sub>\u03b2<jats:sub>3<\/jats:sub>activation was also affected following the activation of platelets via<jats:styled-content style=\"fixed-case\">GPVI<\/jats:styled-content>\u2010Fc\u03b3<jats:styled-content style=\"fixed-case\">RII<\/jats:styled-content>a or<jats:styled-content style=\"fixed-case\">PAR<\/jats:styled-content>1. Finally, amotosalen illumination as such is sufficient to induce platelet damage, with no additional measurable effect of the chemical adsorption step. Gamma irradiation caused no significant difference compared to controls on any time\u2010point or for any parameter.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Both<jats:styled-content style=\"fixed-case\">PCT<\/jats:styled-content>s significantly reduce thrombus formation rate but by different biochemical mechanisms.<\/jats:p><\/jats:sec>","DOI":"10.1111\/vox.12231","type":"journal-article","created":{"date-parts":[[2014,12,30]],"date-time":"2014-12-30T15:38:12Z","timestamp":1419953892000},"page":"328-339","source":"Crossref","is-referenced-by-count":36,"title":["Riboflavin and amotosalen photochemical treatments of platelet concentrates reduce thrombus formation kinetics<i>in vitro<\/i>"],"prefix":"10.1111","volume":"108","author":[{"given":"B.","family":"Van Aelst","sequence":"first","affiliation":[{"name":"Transfusion Research Center Belgian Red Cross\u2010Flanders Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0052-8852","authenticated-orcid":false,"given":"H. B.","family":"Feys","sequence":"additional","affiliation":[{"name":"Transfusion Research Center Belgian Red Cross\u2010Flanders Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Devloo","sequence":"additional","affiliation":[{"name":"Transfusion Research Center Belgian Red Cross\u2010Flanders Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Vanhoorelbeke","sequence":"additional","affiliation":[{"name":"Laboratory for Thrombosis Research KU Leuven Kulak Kortrijk Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Vandekerckhove","sequence":"additional","affiliation":[{"name":"Blood Service of the Belgian Red Cross\u2010Flanders Mechelen Belgium"},{"name":"Department of Public Health and Primary Care Catholic University of Leuven Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Compernolle","sequence":"additional","affiliation":[{"name":"Transfusion Research Center Belgian Red Cross\u2010Flanders Ghent Belgium"},{"name":"Blood Service of the Belgian Red Cross\u2010Flanders Mechelen Belgium"},{"name":"Faculty of Medicine and Health Sciences University of Ghent Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,12,30]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2005.04.001"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1159\/000323845"},{"issue":"2","key":"e_1_2_8_4_1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1423-0410.2000.tb00065.x","article-title":"The use of riboflavin for the inactivation of pathogens in blood products","volume":"78","author":"Goodrich RP","year":"2000","journal-title":"Vox Sang"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1997.37497265344.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12106"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-1097.2004.tb00043.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1562\/0031-8655(2002)0750561BAOCES2.0.CO2"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2011.01477.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03323.x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2003.00588.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01167.x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2012.03923.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/09537104.2012.709653"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04492.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000027102.53875.47"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000093279.36628.12"},{"key":"e_1_2_8_18_1","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1182\/blood.V92.5.1518","article-title":"A double\u2010blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans","volume":"92","author":"Bossavy JP","year":"1998","journal-title":"Blood"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2011.03.002"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1993.tb08280.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12636"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12566"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2012.01614.x"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2005.04350.x"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02092.x"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.13.5754"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)11086-3"},{"key":"e_1_2_8_28_1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1055\/s-0038-1647363","article-title":"Synthetic RGDS\u2010containing peptides of von Willebrand factor inhibit platelet adhesion to collagen","volume":"64","author":"Fressinaud E","year":"1990","journal-title":"Thromb Haemost"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12460"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02681.x"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2005.12.003"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(83)90553-3"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07209.x"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2009.01.013"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2005.04381.x"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1042\/BST20120327"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V57.5.956.956"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12020"},{"key":"e_1_2_8_39_1","first-page":"63A","article-title":"Aggregation and proteomic analyses of intercept\u2010treated platelets","volume":"52","author":"Prudent M","year":"2012","journal-title":"Transfusion"},{"key":"e_1_2_8_40_1","first-page":"CD009072","article-title":"Pathogen\u2010reduced platelets for the prevention of bleeding","volume":"3","author":"Butler C","year":"2013","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fvox.12231","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.12231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T17:33:01Z","timestamp":1747330381000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.12231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,30]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.1111\/vox.12231"],"URL":"https:\/\/doi.org\/10.1111\/vox.12231","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,30]]}}}